Shukra Pharmaceuticals Ltd — Dividend/Bonus, 07-05-2026: Corp. Action

The company's board approved financial results for the quarter and full year. Annually, standalone revenue was ₹56.71 Cr with a net profit of ₹22.05 Cr, and consolidated revenue reached ₹56.73 Cr with a net profit of ₹22.06 Cr. A final dividend of Re 0.01 (1%) per equity share of Re 1/- was proposed, pending shareholder approval. Further, 17,35,000 equity shares were allotted to promoters via warrant conversion, raising Rs. 4.42 Cr and increasing paid-up capital to ₹43.96 Cr. A total of 29,08,000 warrants remain outstanding. No deviation was reported in prior preferential warrant fund utilization.